EUVIMEDEUVIMED entdecken
Crossref

Use of research‐grade radioisotopes for in‐human recovery and survival studies

Bethany L Brown iD, Michael Wellington, Stephanie Cleeton, Alexus Brown, Sandra Zittermann, Zohreh Tatari Calderone iD, Pamela Whitley

Transfusion · 2025

DOI: 10.1111/trf.18468 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transfusion, 2025. Verfasst von Bethany L Brown und 6 weiteren Autor:innen. Beteiligte Einrichtung: American Red Cross, Washington, DC, USA. Hauptthemen laut MEDLINE: Erythrocytes, Chromium Radioisotopes, Erythrocyte Transfusion, Isotope Labeling. Die Arbeit nennt 8 Literaturangaben. Gefördert von: American Red Cross.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives Red blood cells ( RBCs ) and platelets are evaluated for in vivo quality using recovery and survival measurements in healthy volunteers. Radiolabeling is the standard method for tracking blood cells post‐transfusion. The supply of chromium‐51 ( 51 Cr) manufactured under Good Manufacturing Practices ( GMP ) has been challenging, and in 2024, the only remaining supplier ceased production. Now, only research‐grade 51 Cr is available, requiring risk control measures. Simultaneously, the Pyrophosphate ( PYP ) kits used to condition RBCs for technetium‐99m ( 99 mTc) labeling are also no longer available. This report summarizes validations performed leading to reinfusions of blood cells labeled with a new kit for 99 mTc RBC labeling and research‐grade 51 Cr . Materials and Methods Three validations were conducted to confirm: (1) labeling efficiency of an alternative kit for 99 mTc labeling RBCs, (2) safety and labeling efficiency using research‐grade 51 Cr, and (3) the ability of the Pyrosate®‐Rapid Endotoxin Detection (PRED) kit to detect pyrogens in research‐grade material and in end‐products for in vivo use.

Results

Labeling efficiency of RBCs with 99 mTc using the Ultratag™ RBC kit was >98% and demonstrated consistency in labeling across different sample preparation conditions. Filtration of the radioisotope stock and endotoxin testing of the infusate served as effective risk mitigation steps, supporting safe use of research‐grade 51 Cr, with labeling efficiency >98%.

Conclusions

We validated the use of research‐grade 51 Cr, an updated kit for 99 mTc labeling, and endotoxin testing for in vivo reinfusion of research‐grade 51 Cr labeled blood cells, and have infused >30 research participants with these changes under US FDA–approved protocols.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErythrocytesChromium RadioisotopesErythrocyte TransfusionIsotope LabelingHumansTechnetiumCell Survival

Stichwörter der Autor:innen

in vivo recovery and survivalradiolabelingred blood cell labeling

Substanzen

Chromium RadioisotopesTechnetium

Autor:innen und Institutionen

  • American Red Cross, Washington, DC, USA.

ORCID-Profile: Bethany L Brown, Zohreh Tatari Calderone

Förderung

  • American Red Cross

Zitieren

APA

Brown, B. L., Wellington, M., Cleeton, S., Brown, A., Zittermann, S., Calderone, Z. T., & Whitley, P. (2025). Use of research‐grade radioisotopes for in‐human recovery and survival studies. Transfusion. https://doi.org/10.1111/trf.18468

Vancouver

Brown BL, Wellington M, Cleeton S, Brown A, Zittermann S, Calderone ZT, et al. Use of research‐grade radioisotopes for in‐human recovery and survival studies. Transfusion. 2025. doi:10.1111/trf.18468

BibTeX
@article{Brown2025,
  author = {Brown, Bethany L and Wellington, Michael and Cleeton, Stephanie and Brown, Alexus and Zittermann, Sandra and Calderone, Zohreh Tatari and Whitley, Pamela},
  title = {Use of research‐grade radioisotopes for in‐human recovery and survival studies},
  journal = {Transfusion},
  year = {2025},
  doi = {10.1111/trf.18468}
}
Kostenlos starten →